RECRUITINGINTERVENTIONAL

Identification of Hepatic Fibrosis Using 4D-MRI

Noninvasive Stage Identification of Hepatic Fibrosis Using 4D-MRI

About This Trial

To date, no specific treatment options exist for liver diseases, and there is a large global effort to find drugs that will halt liver disease progression in these patients.Liver fibrosis staging is essential as a diagnostic/prognostic measure and there is an increasing demand for accurate non-invasive liver stiffness measurement tools. This research project proposes a novel MR-based quantitative Liver Deformation Biomarker (qLDB) approach for non-invasive liver fibrosis assessment by using a new technique called 4D-MRI. 4D-MRI allows to overcome the limitations of currently used techniques. Hence, 4D-MRI may help to identify a novel biomarker for non-invasive staging of liver fibrosis , and therefore improve the final diagnosis of patients suffering from liver diseases.

Who May Be Eligible (Plain English)

Who May Qualify: - age ≥ 18 years - (a) Patients with diagnosed by tissue sample (biopsy-confirmed) chronic liver disease, including NAFLD, ALD, viral hepatitis B and C, genetic (e.g. Wilson disease, hemochromatosis) or autoimmune liver disease - (b) Patients with acute liver inflammation or cardiac blood congestion to the liver (as assessed by laboratory values, imaging findings and clinical history) - ability to understand and consent to participate in this study Who Should NOT Join This Trial: - Medical implant like cardiac pacemaker, pump, hip prosthesis - Metallic objects in the body (e.g. splinters after an accident) - Persons who have undergone brain or cardiac surgery - Claustrophobia - Body Weight \>140kg or as provided by the MR manufacturer - Pregnant and lactating women - (a) Active hepatocellular carcinoma (HCC) (remark: patients with a history of HCC and curative treatment can be included) - (a) CHILD C cirrhosis - (a) and (b) Patients with overt ascites (except if they respond to diuretic treatment and the ascites resolves) - (c) Metabolic syndrome, BMI \>30 kg/m2 - (c) Acute or chronic liver disease - Patients not willing or able to give a written willing to sign a consent form Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * age ≥ 18 years * (a) Patients with histologically confirmed chronic liver disease, including NAFLD, ALD, viral hepatitis B and C, genetic (e.g. Wilson disease, hemochromatosis) or autoimmune liver disease * (b) Patients with acute liver inflammation or cardiac blood congestion to the liver (as assessed by laboratory values, imaging findings and clinical history) * ability to understand and consent to participate in this study Exclusion Criteria: * Medical implant like cardiac pacemaker, pump, hip prosthesis * Metallic objects in the body (e.g. splinters after an accident) * Persons who have undergone brain or cardiac surgery * Claustrophobia * Body Weight \>140kg or as provided by the MR manufacturer * Pregnant and lactating women * (a) Active hepatocellular carcinoma (HCC) (remark: patients with a history of HCC and curative treatment can be included) * (a) CHILD C cirrhosis * (a) and (b) Patients with overt ascites (except if they respond to diuretic treatment and the ascites resolves) * (c) Metabolic syndrome, BMI \>30 kg/m2 * (c) Acute or chronic liver disease * Patients not willing or able to give a written informed consent

Treatments Being Tested

DIAGNOSTIC_TEST

4D-MRI

Novel MR-imaging (MRI) and postprocessing techniques, making it possible to capture breathing-induced abdominal motion, including liver motion, under free-breathing. For the first time, these techniques - called 4D-MRI - were able to capture the abdominal organs with high spatial resolution in 3-dimensions at a high frame rate of 2-3 Hz and enabled an entirely new insight into the human body.

Locations (2)

Kantonsspital Baselland (KSL)

Liestal, Basel-Landschaft, Switzerland

University Hospital Basel

Basel, Canton of Basel-City, Switzerland